Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma

Background The relevance of estrogen receptor(ER) expression in pancreatic ductal adenocarcinoma (PDAC) is largely unknown. Clinical trials targeting ER with selective estrogen receptor modulatorsin pancreatic cancer did not show any benefit. Here, we analyze the impact of recently characterized ER isoform beta on survival in a cohort of patients with resected PDAC.